Objective: To observe the effect of combined therapy regimen on ovarian function, MMP and related factors in patients with adenomyosis under the condition of LNG-IUS drug therapy. Methods: A total of 110 patients with...Objective: To observe the effect of combined therapy regimen on ovarian function, MMP and related factors in patients with adenomyosis under the condition of LNG-IUS drug therapy. Methods: A total of 110 patients with adenomyosis from October 2015 to October 2017 were retrospectively analyzed and divided into control group and observation group. The control group of 54 patients, observation group of 56 patients. All patients were treated with LNG-IUS system in the 4th to 7th day of the menstrual cycle. The patients in the observation group were treated with TCRE on the basis of LNG-IUS. The fasting venous blood was taken from the third day of menstruation and the luteinizing hormone (LH (MMP-2, MMP-3, MMP-9) were detected by enzyme-linked immunosorbent assay (ELISA). The levels of VEGF, CA125 and IGF-1 were detected by enzyme-linked immunosorbent assay (ELISA) Ang-2, PGE2 levels were compared. Results: There was no significant difference in LH, FSH and E2 levels between the two groups before treatment. After treatment, the levels of LH, FSH and E2 were significantly higher in the two groups compared with those before treatment. (2) Before treatment, the levels of serum MMP-2, MMP-3, MMP-2 and MMP-2 in the two groups were significantly higher than those in the control group. The levels of MMP-2, MMP-3 and MMP-9 in the serum of the two groups were significantly lower than those before treatment, and there was no significant difference between the two groups. (3) Before treatment, serum levels of VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lower than those in the control group. The levels of serum VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lower than those before treatment. The patients in the observation group were significantly lower than the control group, there was significant difference between the two groups. Conclusion The levels of serum MMP-2, MMP-3, MMP-9 and VEGF, CA125, IGF-1, Ang-2 and MMP-2 in patients with adenomyosis were treated with TCRE on the basis of LNG-IUS drug therapy. PGE2 level, indicating that TCRE combined with LNG-IUS drug therapy can not only improve the efficacy, improve the patient's menstrual flow, dysmenorrhea and other symptoms, control the progression of the disease, but also by regulating the expression of certain factors play a role in improving ovarian function, worthy of clinical On the promotion and application.展开更多
文摘Objective: To observe the effect of combined therapy regimen on ovarian function, MMP and related factors in patients with adenomyosis under the condition of LNG-IUS drug therapy. Methods: A total of 110 patients with adenomyosis from October 2015 to October 2017 were retrospectively analyzed and divided into control group and observation group. The control group of 54 patients, observation group of 56 patients. All patients were treated with LNG-IUS system in the 4th to 7th day of the menstrual cycle. The patients in the observation group were treated with TCRE on the basis of LNG-IUS. The fasting venous blood was taken from the third day of menstruation and the luteinizing hormone (LH (MMP-2, MMP-3, MMP-9) were detected by enzyme-linked immunosorbent assay (ELISA). The levels of VEGF, CA125 and IGF-1 were detected by enzyme-linked immunosorbent assay (ELISA) Ang-2, PGE2 levels were compared. Results: There was no significant difference in LH, FSH and E2 levels between the two groups before treatment. After treatment, the levels of LH, FSH and E2 were significantly higher in the two groups compared with those before treatment. (2) Before treatment, the levels of serum MMP-2, MMP-3, MMP-2 and MMP-2 in the two groups were significantly higher than those in the control group. The levels of MMP-2, MMP-3 and MMP-9 in the serum of the two groups were significantly lower than those before treatment, and there was no significant difference between the two groups. (3) Before treatment, serum levels of VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lower than those in the control group. The levels of serum VEGF, CA125, IGF-1, Ang-2 and PGE2 in the two groups were significantly lower than those before treatment. The patients in the observation group were significantly lower than the control group, there was significant difference between the two groups. Conclusion The levels of serum MMP-2, MMP-3, MMP-9 and VEGF, CA125, IGF-1, Ang-2 and MMP-2 in patients with adenomyosis were treated with TCRE on the basis of LNG-IUS drug therapy. PGE2 level, indicating that TCRE combined with LNG-IUS drug therapy can not only improve the efficacy, improve the patient's menstrual flow, dysmenorrhea and other symptoms, control the progression of the disease, but also by regulating the expression of certain factors play a role in improving ovarian function, worthy of clinical On the promotion and application.
